TrialBritish journal of cancer2023

A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma.

Juanita Lopez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.